Efficacy and Safety of Systemic Treatments for Psoriasis in Elderly Patients

Clara De Simone, Stefano Piaserico, Andrea Conti, Francesco Lo Console, Francesca Prestinari, Annamaria Mazzotta, Giulio Gualdi, Claudio Guarneri, Stefania Borsari, Nicoletta Cassano

Research output: Contribution to journalArticle

54 Citations (Scopus)


Management of psoriasis in elderly patients can be challenging, because of the impairment of immune system efficiency and the presence of comorbidities that contra-indicate systemic therapies. We studied the safety and efficacy of systemic traditional and biological treatments in 187 consecutive psoriatic patients aged > 65 years. At week 12 of therapy, Psoriasis Area and Severity Index 75 was avieved by 49%, 27%, 46% and 31% of patients who received methotrexate, acitretin, cyclosporine or PUVA, and 64.1%, 64.7%, 93.3%, 57.1% and 100% of patients who received etanercept, adalimumab, infliximab, efalizumab and ustekinumab. The rate of adverse events was 0.12, 0.32, 1.4 and 0.5 per patient-year in the methotrexate, acitretin, cyclosporine and PUVA groups and 0.11, 0.35, 0.19, 0.3 and 0.26 in the etanercept, adalimumab, infliximab, efalizumab and ustekinumab groups. Traditional drugs were less effective than biologics in our elderly population. Etanercept was associated with a lower rate of adverse events compared with other treatments.
Original languageEnglish
Pages (from-to)1-2
Number of pages2
JournalActa Dermato-Venereologica
Publication statusPublished - 2013


  • psoriasis


Dive into the research topics of 'Efficacy and Safety of Systemic Treatments for Psoriasis in Elderly Patients'. Together they form a unique fingerprint.

Cite this